Q2 EPS Estimates for HeartSciences Raised by Maxim Group

HeartSciences Inc. (NASDAQ:HSCS) – Research analysts at Maxim Group upped their Q2 2027 EPS estimates for shares of HeartSciences in a report issued on Thursday, September 17th. Maxim Group analyst A. Klee now forecasts that the company will post earnings of ($0.72) per share for the quarter, up from their previous estimate of ($0.75). The consensus estimate for HeartSciences’ current full-year earnings is ($2.99) per share. Maxim Group also issued estimates for HeartSciences’ Q3 2027 earnings at ($0.70) EPS, Q4 2027 earnings at ($0.64) EPS, FY2027 earnings at ($2.88) EPS, Q1 2028 earnings at ($0.65) EPS, Q2 2028 earnings at ($0.61) EPS, Q3 2028 earnings at ($0.46) EPS, Q4 2028 earnings at ($0.32) EPS and FY2028 earnings at ($2.01) EPS.

Several other equities analysts also recently weighed in on HSCS. Weiss Ratings restated a “sell (e+)” rating on shares of HeartSciences in a research report on Wednesday, June 24th. Wall Street Zen upgraded HeartSciences from a “sell” rating to a “hold” rating in a report on Sunday. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $8.00.

HeartSciences Trading Down 10.0%

NASDAQ:HSCS opened at $4.68 on Monday. HeartSciences has a 12 month low of $1.63 and a 12 month high of $5.25. The stock has a 50 day moving average of $2.85 and a two-hundred day moving average of $2.45. The firm has a market cap of $22.46 million, a P/E ratio of -1.45 and a beta of 1.85.

HeartSciences (NASDAQ:HSCS) last posted its quarterly earnings data on Monday, September 14th. The company reported ($0.86) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.72) by ($0.14). The business had revenue of $0.00 million for the quarter, compared to analyst estimates of $0.10 million.

About HeartSciences

HeartSciences, Inc is a medical technology company focused on improving the detection and management of cardiovascular disease. The company develops electrocardiography (ECG) technologies intended to provide clinicians with additional information about cardiac function using a test that is widely available in healthcare settings.

Its principal technology is the MyoVista wavECG system, which applies proprietary signal-processing methods, including wavelet analysis, to standard 12-lead ECG data.